Conversely, the therapeutic benefits of using multiple injections of the smaller radioligands 212Pb-DOTAMTATE, 225Ac-L1, and 149Tb-PSMA-617 have been demonstrated [22,48,82], and potentially explained by the intratumoral penetration and the possibility of increasing the cumulative dose to the tumor by extending the treatment duration, which allows for systemic toxicity recovery. The gene discussed is FOLH1; the disease is neoplasm.